

REMARKS

Favorable reconsideration is respectfully requested in view of preceding amendments and the following comments.

The newly presented claims find clear and complete antecedent support in the original claims, in the disclosure on pages 6 to 9 of the specification and, more particularly in paragraphs 3 to 6 on page 7 of the specification.

The rejection of claims 1 to 9 and 11 to 20 "under 35 U.S.C. 112, second paragraph" is respectfully traversed. It appears that the Examiner may be confusing the difference between breadth and indefiniteness. Although nothing is found in the statute which precludes breadth other than prior art, Applicants have taken this opportunity to follow the Examiner's recommendation to avoid this issue entirely by limiting the product claims to different encapsulated administration forms.

The rejection of claims 1 to 9 and 11 to 20 "under 35 U.S.C. 102(b) as being anticipated by WO 97/02020" (Dietrich) is also respectfully traversed. Dietrich neither discloses nor suggests having two different administration forms of the active ingredient to which all of Applicants' claims are limited, in a single encapsulated form.


Application No. 09/762,302
Attorney Docket No. P66333US0

Having overcome all outstanding grounds of rejection, the application is now in condition for allowance, and early action toward that end is respectfully solicited.

Respectfully submitted,

JACOBSON·HOLMAN PLLC

By:


Irwin M. Aisenberg
Reg. No. 19,007

400 Seventh Street, N.W.
The Jenifer Building
Washington, D.C. 20004
Tel.: (202) 638-6666
Attorney Docket No. P66333US0
Date: April 29, 2003
IMA:jmp
R:\SHARED\P66333US0-Amendment.wpd